KCM
RMD icon

Kames Capital Management’s ResMed RMD Stock Holding History

Kames Capital Management’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-21,732
Closed -$1.1M – 188
2014
Q2 		$1.1M Buy
+21,732
New +$1.08M 0.04% 145

Other funds holding RMD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
CBOA
Commonwealth Bank of Australia Sydney, NSW, Australia $231M AUM
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Kames Capital Management's RMD Position: Q3 2014 in Review

Kames Capital Management sold out of ResMed (RMD) in Q3 2014, closing a stake of 21,732 shares — an estimated $1.1M sold.

Kames Capital Management first reported a position in RMD in Q2 2014 and held it in 1 quarter. The position peaked at $1.1M in Q2 2014. 301 funds tracked by Wall St. Rank hold RMD as of Q3 2014.

  • Kames Capital Management reported no remaining ResMed position as of Q3 2014 after selling out during the quarter.
  • Kames Capital Management sold 21,732 ResMed shares in Q3 2014, an estimated $1.1M.
  • Kames Capital Management first reported a position in ResMed in Q2 2014 and held it in 1 quarter.
  • Kames Capital Management's ResMed position peaked at $1.1M in Q2 2014.
  • 301 funds tracked by Wall St. Rank held ResMed as of Q3 2014.

Based on Kames Capital Management's 13F filing for Q3 2014, filed 20 Oct 2014.